FibroGen Inc (NASDAQ:FGEN)’s stock price traded down 14.9% during trading on Monday following insider selling activity. The stock traded as low as $35.16 and last traded at $35.40, 2,777,438 shares were traded during mid-day trading. An increase of 288% from the average session volume of 715,239 shares. The stock had previously closed at $41.62.
Specifically, insider K Peony Yu sold 3,419 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $40.92, for a total transaction of $139,905.48. Following the completion of the transaction, the insider now owns 175,240 shares in the company, valued at $7,170,820.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Christine Chung sold 5,625 shares of the business’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $36.58, for a total value of $205,762.50. Following the transaction, the senior vice president now owns 145,253 shares of the company’s stock, valued at approximately $5,313,354.74. The disclosure for this sale can be found here. Insiders have sold 86,756 shares of company stock valued at $3,644,083 in the last 90 days. Company insiders own 7.83% of the company’s stock.
Several research analysts have issued reports on the company. Zacks Investment Research upgraded FibroGen from a “hold” rating to a “buy” rating and set a $51.00 target price for the company in a research report on Tuesday, August 13th. TheStreet upgraded FibroGen from a “d+” rating to a “c” rating in a research report on Tuesday, August 13th. BidaskClub upgraded FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, October 17th. ValuEngine upgraded FibroGen from a “hold” rating to a “buy” rating in a research report on Friday, November 8th. Finally, Mizuho reaffirmed a “positive” rating and set a $72.00 price target (up previously from $65.00) on shares of FibroGen in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $58.33.
The company’s 50 day moving average price is $38.50 and its two-hundred day moving average price is $41.81. The company has a quick ratio of 9.71, a current ratio of 9.73 and a debt-to-equity ratio of 0.07. The stock has a market cap of $3.62 billion, a P/E ratio of -34.52 and a beta of 1.84.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.02. FibroGen had a net margin of 13.90% and a return on equity of 9.01%. The firm had revenue of $33.17 million during the quarter, compared to the consensus estimate of $31.61 million. During the same quarter in the previous year, the firm posted ($0.50) earnings per share. The company’s revenue was up 14.3% on a year-over-year basis. As a group, equities research analysts forecast that FibroGen Inc will post -0.37 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the company. Captrust Financial Advisors bought a new stake in shares of FibroGen during the second quarter valued at approximately $90,000. US Bancorp DE raised its stake in shares of FibroGen by 79.7% during the second quarter. US Bancorp DE now owns 2,172 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 963 shares in the last quarter. Usca Ria LLC bought a new position in FibroGen in the third quarter worth approximately $123,000. Convergence Investment Partners LLC bought a new position in FibroGen in the third quarter worth approximately $137,000. Finally, Nisa Investment Advisors LLC raised its stake in FibroGen by 729.8% in the third quarter. Nisa Investment Advisors LLC now owns 3,900 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 3,430 shares in the last quarter. 69.03% of the stock is owned by hedge funds and other institutional investors.
FibroGen Company Profile (NASDAQ:FGEN)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
See Also: What is a front-end load?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.